Evidence map›Paper›PMID 33419447›Full record

ArticleHealth and quality of life outcomes2021

Translation and validation of the Traditional Chinese version of the COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (Version 2).

Dorothy N S Chan, Kai Chow Choi, Marques S N Ng, Weijie Xing, Bernard M H Law, Pui Shan Ho, Cecilia Au, Mandy Chan, Man Tong, Wai Man Ling and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Health and quality of life outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Financial toxicity in female patients with breast cancer: a national cross-sectional study in China.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dorothy N S ChanThe Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, 7/F Esther Lee Building, Shatin, the New Territories, Hong Kong, China.
Kai Chow ChoiThe Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, 7/F Esther Lee Building, Shatin, the New Territories, Hong Kong, China.
Marques S N NgThe Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, 7/F Esther Lee Building, Shatin, the New Territories, Hong Kong, China.
Weijie XingSchool of Nursing, Fudan University, Shanghai, China.
Bernard M H LawThe Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, 7/F Esther Lee Building, Shatin, the New Territories, Hong Kong, China.
Pui Shan HoDepartment of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China.
Cecilia AuDepartment of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
Mandy ChanDepartment of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China.
Man TongDepartment of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China.
Wai Man LingDepartment of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
Maggie ChanDepartment of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
Suzanne S S MakDepartment of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China.
Raymond J ChanSchool of Nursing, Queensland University of Technology, Brisbane, Australia.
Winnie K W SoThe Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, 7/F Esther Lee Building, Shatin, the New Territories, Hong Kong, China. winnieso@cuhk.edu.hk.ORCID http://orcid.org/0000-0001-9243-2924

Funding

Chinese University of Hong Kong CA-1806
6 · The paper itself

Abstract

backgroundCancer patients often experience severe financial distress due to the high cost of their treatment, and strategies are needed to objectively measure this financial distress. The COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) is one instrument used to measure such financial distress. This study aimed to translate the COST-FACIT (Version 2) [COST-FACIT-v2] instrument into traditional Chinese (COST-FACIT-v2 [TC]) and evaluate its psychometric properties.

methodsThe Functional Assessment of Chronic Illness Therapy (FACIT) translation method was adopted. The translated version was reviewed by an expert panel and by 20 cancer patients for content validity and face validity, respectively, and 640 cancer patients, recruited from three oncology departments, completed the translated scale. Its reliability was evaluated in terms of internal consistency and test-retest reliability. Confirmatory factor analysis has been used to evaluate the one- and two-factor structures of the instrument reported in the literature. The convergent validity was examined by the correlation with health-related quality of life (HRQoL) and psychological distress. Known-group validity was examined by the difference in the COST-FACIT-v2 (TC) total mean score between groups with different income levels and frequency of health care service use.

resultsThe COST-FACIT-v2 (TC) showed good content and face validity and demonstrated high internal consistency (Cronbach's alpha, 0.86) and acceptable test-retest reliability (intraclass correlation coefficient, 0.71). Confirmatory factor analysis showed that the one- and two-factor structures of the instrument that have been reported in the literature could not be satisfactorily fitted to the data. Psychological distress correlated significantly with the COST-FACIT-v2 (TC) score (r = 0.47; p < 0.001). HRQOL showed a weak to moderate negative correlation with the COST-FACIT-v2 (TC) score (r = - 0.23 to - 0.46; p < 0.001). Significant differences were seen among the COST-FACIT-v2 (TC) scores obtained in groups of different income level and frequency of health care service use.

conclusionsThe COST-FACIT-v2 (TC) showed some desirable psychometric properties to support its validity and reliability for assessing cancer patients' level of financial toxicity.

Indexed as

Cost of IllnessAdultAgedAsian PeopleChronic DiseaseFactor Analysis, StatisticalFemaleHumansMaleMiddle AgedNeoplasmsPsychometricsReproducibility of ResultsSocioeconomic FactorsSurveys and QuestionnairesTranslationsComprehensive score for financial toxicityPsychometric testingReliabilityValidity

Identifiers

PMID33419447
PMCPMC7792341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.